Nathalie Bardy-Bouxin

TL;DR: In heavily pretreated patients with locally advanced or metastatic breast cancer, 75 and 250 mg temsirolimus showed antitumor activity and 75 mg Temsiro Limus showed a generally tolerable safety profile.

TL;DR: Patients who received bosutinib had significantly higher rates of MMR and CCyR and achieved responses faster than those who received imatinib, indicating bosut inib may be an effective first-line treatment for chronic-phase CML.

TL;DR: Bosutinib showed promising efficacy in prolonging time to progression in chemotherapy-pretreated patients with locally advanced or metastatic breast cancer and was generally well tolerated, with a safety profile different from that of the Src/Abl tyrosine kinase inhibitor dasatinib in a similar patient population.

TL;DR: Bosutinib was generally well tolerated in patients with solid tumor malignancies, with the main toxicity being gastrointestinal.

TL;DR: Responses were durable in ∼50% AP responders at 4 years (∼25% BP patients responded at year 1, suggesting possible bridge‐to‐transplant role in BP patients); toxicity was manageable.